Clinical Trial Update: Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the clinical value of traditional Chinese medicine as adjuvant therapy for triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: UNKNOWN